Page 17 - Sanket Koul

Aurobindo Pharma Q1 PAT falls 10% on drop in API sales, US market revenue

Aurobindo Pharma reports a 10.2% YoY drop in Q1 FY26 PAT due to lower API sales and US market revenue, while its European and growth markets continue to show positive momentum

DLF Q1 FY26 results: PAT up 18% on record sales of over ₹11,425 crore

Revenue nearly doubles to Rs 2,716 crore in Q1 FY26, as DLF meets strong demand for luxury homes and continues expansion in Mumbai, Goa, and Gurugram

Delhi NCR-based Nimbus Group to invest ₹1,100 cr in stalled luxury project

Nimbus Group will invest Rs 1,100 crore to revive the stalled Arista Luxe Phase II project in Noida, aiming for completion by 2029 and offering luxury apartments priced between Rs 4-6 crore

Retail real estate sees higher leasing in H1 2025, driven by stable demand

Retail leasing in India rose 21% in H1 2025 compared to the previous year. Experts predict significant new supplies in Delhi NCR, Mumbai, and Hyderabad in H2 2025.

DRL to Cipla: Pharma Inc firms up plans to launch anti-obesity drugs

Push comes as patents are set to expire in March 2026

Gurugram circle rate hike likely to price out low, mid-income buyers

Gurugram's second circle rate hike in eight months raises acquisition costs and stamp duties, with developers warning of pressure on mid-income housing demand

Mankind Pharma Q1 PAT drops 17.4% despite 24% revenue growth, costs surge

Input and finance costs weigh on profitability; chronic, consumer health and BSV acquisition support top line

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Trump on Wednesday called India's tariffs on US exports among the highest in the world, with the most strenuous non-monetary trade barriers of any country, in a post on Truth Social

Healthcare body seeks regulatory reforms in meeting with Niti Aayog

Nathealth has proposed a digital single-window system to Niti Aayog to ease the healthcare sector's compliance load, citing inefficiencies and duplication across ministries

Torrent Pharma Q1 results: PAT up 20% on robust sales across territories

Torrent Pharmaceuticals reports Rs 548 crore Q1 net profit, led by strong growth in India, the US, and Brazil, with chronic therapies and top brands driving momentum

NephroPlus files DRHP, aims to raise ₹353.4 crore via fresh equity issue

The Hyderabad based firm aims to raise ₹353.4 crore through a fresh issue of equity shares. Market sources claim the total issue size could touch ₹2000 crore

Mandatory to conduct audit of safety in schools: Govt tells states, UTs

This comes a day after a portion of a government school in Rajasthan's Jhalawar district collapsed on Friday, killing seven children and leaving 28 injured

Egg-freezing sees demand surge across cities as infertility rises

Rising infertility, delayed motherhood and increased awareness are driving demand for egg freezing across India, with clinics reporting a surge in inquiries from urban women

Elan Group repays Rs 875 cr debt to Asia Pragati Strategic Investment Fund

Elan Group's strategic debt repayment strengthens its financial position, creating room for investment in future projects and land acquisitions

Natco Pharma offers to acquire 35% in Adcock Ingram for ₹2,000 crore

Expected to be closed in 4 months, deal to facilitate Indian firm's entry into Africa

IHH inks Fortis-Gleneagles O&M deal to strengthen pan-India platform

Under the agreement, Fortis will manage operations of six Gleneagles hospitals and one clinic, earning a monthly fee and expanding its bed capacity and national presence

India needs $2.4 trn to build climate-resilient infra by 2050: World Bank

It recommended implementation of integrated urban flood risk management at national and state levels, with sustainable stormwater management at city level, along with heat mitigation actions

ICMR looks to commercialise malaria vaccine, invites EoIs for tech transfer

According to the EoI, ICMR-RMRCBB will also provide expert guidance and technical support for the production of the vaccine in all phases

CDSCO flags 4 drugs as spurious, 185 not of standard quality for June 2025

CDSCO has flagged four drugs as spurious and 185 others as not of standard quality for June 2025. The list includes antibiotics and heart disease medications. Investigations are underway

CDSCO revises export NOC guidance document for new drug formulations

The CDSCO has updated its guidelines for issuing export NOCs for new drug formulations, including relaxations for FDCs, research-oriented drug batches, and SRA approvals